Matthew Kurian: Day 2 at ASCO25 – and ASCENT-04 Stole the Show!
Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine, posted on LinkedIn:
“Day 2 at ASCO25 — and ASCENT-04 stole the show!
Among PROTACs, ADCs, and biomarker bonanzas, this one’s practice-changing.
ASCENT-04 / KEYNOTE-D19: Sacituzumab + Pembrolizumab in 1L PD-L1+ mTNBC Gilead Sciences
New standard of care in the making:
→ PFS: 11.2 vs 7.8 mo, HR 0.65
→ ORR: 60%, CR: 13%, DOR: 16.5 vs 9.2 mo
→ Fewer discontinuations: 12% vs 31%
What sealed it for me? 81% of chemo+pembro patients crossed over to 2L saci and still couldn’t catch up.
Reinforces a key truth: not everyone gets to 2L — use your best drugs upfront!
Other Day 2 standouts:
VERITAC-2: First oral PROTAC (vepdegestrant) vs fulvestrant
→ PFS: 5.0 vs 2.1 mo in ESR1-mutant MBC
→ <5% dose mods or D/Cs — oral SERD competition heating up
INAVO120 (just published in NEJM Group)
Inavolisib + fulvestrant + palbo in patients relapsing <12m from adjuvant ET
→ PFS: 17.3 vs 7.3 mo, OS: 34.0 vs 27.3 mo
Hyperglycemia was expected — but G3 stomatitis was seen in 6% of folks.
-Great data, but where does this apply with oral SERD plus CDK4/6 combination options that continue to expand? Genetech
DESTINY-Breast06 biomarkers AstraZeneca
→ TDxd worked regardless of PIK3CA, ESR1, BRCA
→ BRCA-mutant PFS: 21.4 vs 5.6 mo (HR 0.14!)
→ ORR and PFS2 benefit across the board
Beyond the data — the people! Got to talk about my experience being a sub specialist in the community setting at the TECAG Lounge with Manmeet Ahluwalia, and why I built my career the way I did and in community! Also got to meet with old/new friends and so many rising stars like Eric Singhi, Shuchi Gulati, and Karan Jatwani who remind me: Science moves forward with relationships.
Then ending the day with the OncBrothers event was great and having the chance with Arya Roy to interview breast oncology rockstars like Hope Rugo and Komal Jhaveri, but also be interviewed about my perspective by Jasmin Hundal, was awesome!
Collaboration, connection, and curiosity — that’s what ASCO is all about.”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023